Latest Treatment Options for Patients with Neuroendocrine Tumors (NETS)
In the last two decades, clinicians have witnessed rapid evolution in the management of neuroendocrine tumors (NETS) in the gastrointestinal tract.
Gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs), is a rare cancer originating from the digestive diffuse endocrine system.
According to Dr Liau Kui Hin, senior consultant at Mt Elizabeth Hospital Singapore, multimodal management of the disease provided by a multi- and trans-disciplinary team remains the key element for ensuring the clinical success of the outcome.
At Mt Elizabeth Singapore, Modern surgery combined with the application of surgical technology (such as minimal access surgery, argon plasma coagulator, harmonic scalpel, etc.) allow operations to be performed with greater precision and speed, less pain, less complications and faster recovery with shorter hospital stays. Better clinical outcome and quality of life can be expected.
Keeping pace with technological developments in NETS treatment, Parkway Hospitals is developing its Peptide Receptor Radionuclide Therapy (PRRT) service. With this treatment option, patients can expect a more personalized treatment, tailored to their cancer type.